Background Cladribine provides immunomodulation through selective targeting of lymphocyte
subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet …

The uneven distribution of multiple sclerosis (MS) across populations can be attributed to
differences in genes and the environment and their interaction. Prevalence and incidence …

Background Interferon beta reduces activity in multiple sclerosis as measured clinically and
by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the …

Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important
for communication, prognostication, design and recruitment of clinical trials, and treatment …

Background: In the 2-year CLARITY study, cladribine tablets significantly improved clinical
and magnetic resonance imaging (MRI) outcomes (vs placebo) in patients with relapsing–…

A total of 754 consecutive patients with relapsing‐remitting multiple sclerosis were investigated
for interferon‐β (IFNβ) antibodies by protein‐G affinity chromatography and antiviral …

… Per Soelberg Sørensen has received personal compensation for serving on scientific
advisory boards, steering committees, independent data monitoring boards in clinical trials, or …

Background: Comorbidity is an area of increasing interest in multiple sclerosis (MS). Objective:
The objective of this review is to estimate the incidence and prevalence of comorbidity in …

To assess factors influencing the success of whole-genome sequencing for mainstream
clinical diagnosis, we sequenced 217 individuals from 156 independent cases or families …

Natalizumab, a highly specific α4-integrin antagonist, is approved for treatment of patients
with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for …